Data / Drug companies / Adare Pharmaceuticals Inc
Adare Pharmaceuticals Inc: 43 products in the FDA NDC directory, labeler code 59917
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Adare Pharmaceuticals Inc (labeler code 59917) lists 43 products in the FDA National Drug Code Directory, covering 1 finished drug by generic name. By type: 41 drugs for further processing, 2 prescription drugs. Its main marketing category is drugs for further processing. The newest product started marketing on April 30, 2024.
The request: Watch Adare Pharmaceuticals Inc (FDA labeler code 59917): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 59917
- Products in commercial distribution
- 43
- Packages
- 47
- Finished drugs by generic name
- 1
- Prescription products
- 2
- Over the counter products
- 0
- Controlled substance products
- Schedule II 11
- Flagged as original packager
- 2 of 2 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- January 1, 1984
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 41 | 95.3% |
| Generic drugs (ANDA) | 2 | 4.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 41 | 95.3% |
| Prescription drugs | 2 | 4.7% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Potassium chloride | 2 | 84 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 15 | 34.9% |
| Capsule, extended release | 9 | 20.9% |
| Powder | 8 | 18.6% |
| Tablet, orally disintegrating | 8 | 18.6% |
| Tablet, extended release | 2 | 4.7% |
| Bead | 1 | 2.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Osmotic Laxative | 2 |
| Potassium Salt | 2 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Valbenazine | 59917-256 | Capsule | Drugs for further processing | April 30, 2024 |
| Valbenazine | 59917-255 | Capsule | Drugs for further processing | April 30, 2024 |
| Valbenazine | 59917-254 | Capsule | Drugs for further processing | April 30, 2024 |
| Potassium chloride | 59917-117 | Tablet, extended release | Drugs for further processing | June 7, 2019 |
| Amphetamine sulfate | 59917-228 | Tablet, orally disintegrating | Drugs for further processing | May 16, 2019 |
| Amphetamine sulfate | 59917-227 | Tablet, orally disintegrating | Drugs for further processing | May 16, 2019 |
| Amphetamine sulfate | 59917-226 | Tablet, orally disintegrating | Drugs for further processing | May 16, 2019 |
| Amphetamine sulfate | 59917-225 | Tablet, orally disintegrating | Drugs for further processing | May 16, 2019 |
| Dexmethylphenidate hydrochloride | 59917-129 | Capsule | Drugs for further processing | October 9, 2018 |
| Dexmethylphenidate hydrochloride | 59917-128 | Capsule | Drugs for further processing | October 9, 2018 |
| Dexmethylphenidate hydrochloride | 59917-127 | Capsule | Drugs for further processing | October 9, 2018 |
| Dexmethylphenidate hydrochloride | 59917-126 | Capsule | Drugs for further processing | October 9, 2018 |
| Dexmethylphenidate hydrochloride | 59917-124 | Capsule | Drugs for further processing | October 9, 2018 |
| Dexmethylphenidate hydrochloride | 59917-123 | Capsule | Drugs for further processing | October 9, 2018 |
| Dexmethylphenidate hydrochloride | 59917-122 | Capsule | Drugs for further processing | October 9, 2018 |
| Potassium chloride extended release | 59917-103 | Capsule | Generic drugs (ANDA) | April 1, 2018 |
| Potassium chloride | 59917-103 | Capsule | Drugs for further processing | April 1, 2018 |
| Potassium chloride | 59917-102 | Capsule | Drugs for further processing | April 1, 2018 |
| Potassium chloride extended release | 59917-102 | Capsule | Generic drugs (ANDA) | April 1, 2018 |
| Potassium chloride | 59917-047 | Tablet, extended release | Drugs for further processing | May 22, 2013 |
| Propranolol hydrochloride | 59917-095 | Capsule, extended release | Drugs for further processing | July 15, 2011 |
| Propranolol hydrochloride | 59917-094 | Capsule, extended release | Drugs for further processing | July 15, 2011 |
| Propranolol hydrochloride | 59917-093 | Capsule, extended release | Drugs for further processing | July 15, 2011 |
| Propranolol hydrochloride | 59917-092 | Capsule, extended release | Drugs for further processing | July 15, 2011 |
| Cyclobenzaprine hydrochloride | 59917-091 | Capsule, extended release | Drugs for further processing | May 12, 2009 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.